Clinical research activities include genetic, imaging, electrophysiological and biomarker studies, as well as phase I-III clinical trials (P. Van Damme, MD, PhD). Basic research activities include generation of small animal models, rodent models and stem cell models for ALS and FTLD, and use them to identify and validate molecular targets for the treatment of these diseases (W. Robberecht MD, PhD, P. Van Damme, MD, PhD, and L. Van Den Bosch, PhD).
Philip van DammeProfessor of Neurology
Professor Philip van Damme is professor of Neurology at the UZ Leuven in Belgium
TUDCA (tauroursodeoxycholic acid) is a small molecule that is being explored for its potential as a treatment for ALSRead more
PreLude (Lithium carbonate)
Within an innovative platform design study, we will evaluate the efficacy of lithium carbonate in UNC13a homozygous patients.Read more
Within an innovative platform design study, we will evaluate the efficacy of Triumeq, a therapy developed for treatment of HIV that has shown to slow progression in ALSRead more